Evaluation of the effect of voxelotor and darbepoetin alfa on hemoglobin levels in patients with sickle cell disease.

IF 2.3 4区医学 Q2 HEMATOLOGY

Expert Review of Hematology Pub Date : 2024-06-01 Epub Date: 2024-05-16 DOI:10.1080/17474086.2024.2352497

Salome Bwayo Weaver, Helen Akinwale, Nkem P Nonyel, La'marcus T Wingate

{"title":"Evaluation of the effect of voxelotor and darbepoetin alfa on hemoglobin levels in patients with sickle cell disease.","authors":"Salome Bwayo Weaver, Helen Akinwale, Nkem P Nonyel, La'marcus T Wingate","doi":"10.1080/17474086.2024.2352497","DOIUrl":null,"url":null,"abstract":"Background: To date, there is limited evidence on patients utilizing both voxelotor and darbepoetin alfa and its impact on hemoglobin levels. The objective is to evaluate the effect of voxelotor and darbepoetin alfa on hemoglobin levels in patients with SCD.Research design and methods: This was a retrospective chart review study that assessed the primary independent variable as the utilization of either voxelotor alone, darbepoetin alfa alone, or the concurrent administration of voxelotor and darbepoetin alfa. Descriptive statistics were utilized to obtain the mean standard deviation for numerical variables and proportions for categorical variables.Results: A total of 23 participants were included in this study. When comparing baseline to 2 months and 3 months, participants on voxelotor alone experienced a 3% decrease and a 6.6% increase in hemoglobin, darbepoetin alfa alone group a 4.3% decrease and a 0.6% increase in hemoglobin and voxelotor and darbepoetin group a 4.4% decrease and a 0.5% decrease in hemoglobin levels. Fifty percent of the participants in the voxelotor group and 6 (66.7%) participants in the voxelotor plus darbepoetin alfa group experienced adverse drug events.Conclusions: Voxelotor resulted in a clinically significant difference in the percent change of hemoglobin from baseline to 3 months.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"255-260"},"PeriodicalIF":2.3000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474086.2024.2352497","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/16 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: To date, there is limited evidence on patients utilizing both voxelotor and darbepoetin alfa and its impact on hemoglobin levels. The objective is to evaluate the effect of voxelotor and darbepoetin alfa on hemoglobin levels in patients with SCD.

Research design and methods: This was a retrospective chart review study that assessed the primary independent variable as the utilization of either voxelotor alone, darbepoetin alfa alone, or the concurrent administration of voxelotor and darbepoetin alfa. Descriptive statistics were utilized to obtain the mean standard deviation for numerical variables and proportions for categorical variables.

Results: A total of 23 participants were included in this study. When comparing baseline to 2 months and 3 months, participants on voxelotor alone experienced a 3% decrease and a 6.6% increase in hemoglobin, darbepoetin alfa alone group a 4.3% decrease and a 0.6% increase in hemoglobin and voxelotor and darbepoetin group a 4.4% decrease and a 0.5% decrease in hemoglobin levels. Fifty percent of the participants in the voxelotor group and 6 (66.7%) participants in the voxelotor plus darbepoetin alfa group experienced adverse drug events.

Conclusions: Voxelotor resulted in a clinically significant difference in the percent change of hemoglobin from baseline to 3 months.

查看原文本刊更多论文

评估Voxelotor和darbepoetin alfa对镰状细胞病患者血红蛋白水平的影响。

背景：迄今为止，关于患者同时使用伏赛洛特和达贝泊汀α及其对血红蛋白水平影响的证据有限。本研究旨在评估伏塞洛特和达贝泊汀α对 SCD 患者血红蛋白水平的影响：这是一项回顾性病历审查研究，评估的主要自变量是单独使用伏赛洛特、单独使用达贝泊汀α或同时使用伏赛洛特和达贝泊汀α的情况。对数字变量采用描述性统计方法得出平均标准偏差，对分类变量采用描述性统计方法得出比例：本研究共纳入 23 名参与者。将基线与 2 个月和 3 个月进行比较，单用伏赛洛特的参与者血红蛋白分别下降了 3% 和上升了 6.6%，单用达贝特α组血红蛋白分别下降了 4.3% 和上升了 0.6%，伏赛洛特和达贝特α组血红蛋白分别下降了 4.4% 和下降了 0.5%。Voxelotor组50%的参与者和Voxelotor加darbepoetin alfa组的6名参与者（66.7%）出现了药物不良事件：结论：Voxelotor使血红蛋白从基线到3个月的百分比变化具有显著的临床意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Hematology HEMATOLOGY-

CiteScore

4.70

自引率

3.60%

发文量

审稿时长

6-12 weeks

期刊介绍： Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.